Cancer Checkpoint Roundup: Big Pharmas Advance Ahead of ASCO
During first-quarter earnings calls and ahead of the upcoming American Society of Clinical Oncology meeting, big pharma execs stressed the importance of developing immunotherapies in a range of cancers and highlighted the progress made so far.
You may also be interested in...
Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.